The European Medicines Agency has begun reviewing a number of new drugs for potential pan-EU marketing authorization including Novartis/BeiGene’s tislelizumab for treating both esophageal cancer and non-small cell lung cancer (NSCLC).
Tislelizumab, an anti-PD-1 monoclonal antibody, is already approved in China in seven indications. A biologics license application (BLA) seeking US...








